Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, completed its $8m Series E round of financing.
The round was led by Caxton Advantage Life Sciences Fund, L.P. and Sanderling Venture Partners, with participation from all of the company’s preferred stockholders.
The funds will support preparations for Phase 3 pivotal trial for Obatoclax (GX15-070) in Small Cell Lung Cancer. In March 2010, Gemin X completed enrollment in its ongoing Phase 2b clinical trial of obatoclax, which is being conducted at more than 60 leading cancer centers, primarily in the United States and Europe.
The company also has several clinical development programs underway, including GMX1777, a novel inhibitor of NAD+ synthesis that has completed a Phase 1 study.
The company also has several clinical development programs underway, including GMX1777, a novel inhibitor of NAD+ synthesis that has completed a Phase 1 study.
Founded in 1998, Gemin X has drug development and executive headquarters in Malvern, Pennsylvania and research and development in Montréal, Canada.
FinSMEs
05/08/2010